Cipla, CSIR-CDRI to jointly develop novel ophthalmic formulation for fungal keratitis

CSIR-CDRI has developed a prototype formulation for an antifungal drug to optimize its delivery in the eye. In preclinical studies, this formulation supports faster resolution of the infection. Cipla will scale up the product, conduct the required studies and seek regulatory approvals for commercialization, ensuring accessibility for those in need.

Commenting on this association Umang Vohra, Managing Director, and Global CEO, Cipla, said, “At Cipla, our growth is centered on our commitment to patients, extending care to communities through patient-centric innovation. This collaboration with CSIR-CDRI is a testament to our commitment to providing innovative and top-quality healthcare solutions to all those in need, encompassing drugs, devices, and diagnostics. With this, we are sustaining our antimicrobial resistance stewardship by investing in anti-infectives and leading industry voice in the fight against AMR.”

Welcoming this partnership, Dr Radha Rangarajan, Director CSIR-CDRI said, “Our research focuses on finding innovative, cost-effective solutions for India’s unmet clinical needs. CDRI scientists have developed a unique ophthalmic formulation of the antifungal drug. This in turn, is expected to accelerate cure and lead to better outcomes. Our collaboration with Cipla will enable the translation of the research into a drug product, with the potential to reduce the burden of disease.”

The two partners have an ongoing collaboration for the development of Levormeloxifene for contraception.

Read also: Cipla eyes inorganic partnerships, acquisitions in US